tbuckley/cabot-search huggingface dataset:
P1.08-037 Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography–Assisted Bronchoscopic Metallic Coil Marking (2nd Version)
Authors: Takanori Miyoshi, Hiroyuki Sumitomo, Koh Uyama, Naoki Hino
Journal: Journal of Thoracic Oncology (2017)
Man with motor neurone disease challenges ban on assisted suicide
Authors: Clare Dyer
Journal: BMJ (2017)

A man with motor neurone disease is mounting a legal challenge to the ban on assisted suicide in England and Wales, in a move that could lead to a change in the law.

Noel Conway, 67, who is not expected to live beyond the next 12 months, argues that the law condemns him to “unimaginable suffering” as his condition deteriorates. “If I let nature take its course, I could effectively become entombed in my own body, or I could die from suffocation or choking,” he said.

Conway, a retired lecturer, is applying for …
OA15.01 Limited Resection Trial for Pulmonary Sub-solid Nodules: Case Selection Based on High Resolution CT: Outcome at Median Follow-up of 105 Months
Authors: Junji Yoshida, Genichiro Ishii, Kanji Nagai, Tomoyuki Hishida, Keiju Aokage, Masahiro Tsuboi, Hiroyuki Ito, Tomoyuki Yokose, Haruhiko Nakayama, Kouzo Yamada
Journal: Journal of Thoracic Oncology (2017)
P3.02a-014 Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
Authors: Jianying Zhou, You Lu, Chin-Hee Chung, Elizabeth Masters, Keith Wilner, Yiyun Tang, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
Glial Fibrillary Acidic Protein as a Plasma Biomarker of Brain Injury in Children with Sickle Cell Disease.
Authors: William J Savage, Zongming Fu, Emily Barron-Casella, Pratima Dulloor, Jacky Jennings, Elizabeth Dackiw, Kimberly Jones, Lisa M. Williams, Barbara Crain, Bruce A Barton, Jennifer Van Eyk, Michael R. DeBaun, James F. Casella, Allen Everett
Journal: Blood (2009)
S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension
Authors: P Caruso, BJ Dunmore, K Schlosser, S Schoors, C Dos Santos, C Perez-Iratxeta, JR Lavoie, L Long, L Hurst, ML Ormiston, A Hata, P Carmeliet, DJ Stewart, NW Morrell
Journal: Thorax (2016)

<h3>Introduction</h3> Pulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms including a heritable form (HPAH) caused primarily by mutations in bone morphogenetic protein receptor type 2 (BMPR2) and an idiopathic form (IPAH). Endothelial cell (EC) dysfunction is considered a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis, heightened permeability and enhanced endothelial proliferation. Substantial changes in bioenergetics of ECs, including higher rates of glycolysis, have been reported in PAH patients. However, the mechanisms underlying alterations in energy production have not been identified. <h3>Methods</h3> We measured glycolysis in blood outgrowth endothelial cells (BOECs) from HPAH patients carrying mutations in BMPR2 and IPAH patients to confirm the metabolic abnormalities previously. We also employed an unbiased genome-wide microarray and proteomic screening approach to detect miRNAs and proteins dysregulated in the same groups to determine the mechanisms underlying abnormal endothelial glycolysis. <h3>Results</h3> HPAH and IPAH BOECs recapitulated the metabolic phenotype previously observed in PAECs. These alterations were found to be associated with the downregulation of miR-124 and the upregulation of its known target, splicing factor polypyrimidine-tract-binding protein (PTBP1). We also demonstrated that increased PTBP1 promotes the switching in expression of two forms of pyruvate kinase, PKM1 and PKM2, resulting in an increase of aerobic glycolysis, consequently increasing cell proliferation (mechanism schematized in Figure 1). Overexpression of miR-124, or siRNA silencing of PTPB1, restoring normal expression levels of PKM2, also restored normal proliferation and glycolysis in HPAH BOECs. Finally, we observed reduced miR-124 and increased PTPB1 and PKM2 expression in a well-established rat model of PAH, characterised by endothelial proliferation, supporting the presence of this mechanism <i>in vivo</i>. <h3>Conclusions</h3> Loss of function of BMPR2 results in the downregulation of miR-124 and consequently in the glycolytic abnormalities reported in PAH ECs. Therefore, the manipulation of this miRNA, or its targets, could represent a novel and effective strategy to achieve clinical benefits in the treatment of PAH.
RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).
Authors: Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Gattoni, Elisabetta Antonioli, Costanza Bogani, Lorenzo Tozzi, Lisa Pieri, Alberto Bosi, Alessandro Rambaldi, Tiziano Barbui, Giovanni Barosi
Journal: Blood (2009)
Phenotypic Correction of Adamts13-Deficient Mice by Early Intra-Amniotic Gene Transfer of Lentiviral Vector Encoding ADAMTS13 Genes.
Authors: Masami Niiya, Masayuki Endo, Philip W. Zoltick, Nidal E. Muvarak, David G. Motto, Alan W. Flake, X. Long Zheng
Journal: Blood (2007)
Repurposing Antiestrogens for Tumor Immunotherapy
Authors: Thomas Welte, Xiang H.-F. Zhang, Jeffrey M. Rosen
Journal: Cancer Discovery (2017)

Abstract Summary: Svoronos and colleagues observed estrogen receptor alpha–positive cells in the tumor stroma of patients with ovarian cancer that appeared to be independent of both the tumor's estrogen receptor status and tumor type. These cells were identified as immunosuppressive myeloid-derived suppressor cells (MDSC) and could be targeted by antiestrogen therapy, thereby leading to the hypothesis that endocrine therapy when combined with immunotherapy may provide a potential therapeutic benefit by helping to reduce immunosuppressive MDSCs. Cancer Discov; 7(1); 17–9. ©2017 AACR. See related article by Svoronos et al., 72.
Effect of Renin Angiotensin System (RAS) Blockade on Hematological Parameters in Patients with Secondary Polycythemia (SP) Associated with Chronic Obstructive Pulmonary Disease (COPD) and Sleep Apnea (SA).
Authors: Jeyanthi Ramanarayanan, Frank Brodzik, Syed Mehdi, Donald Pasquale
Journal: Blood (2006)
del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.
Authors: Leslie A. Andritsos, Jeffrey Jones, Gerard Lozanski, Thomas S. Lin, Kristie A. Blum, Michael R. Grever, David Jarjoura, John C. Byrd, Nyla Heerema
Journal: Blood (2007)
European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.
Authors: Giovanni Martinelli, Jane Apperley, Andreas Reiter, Nicholas P. Cross, Daniela Cilloni, David Grimwade, Andreas Hochhaus, Emanuela Ottaviani, Jan Cools, Lionel Prin, Michele Malagola, C Walz, Claude Preudhomme, Francesca Messa, Michela Rondoni, Enrico Gottardi, Gianantonio Rosti, Cristina Mecucci, Fabrizio Pane, Nicoletta Testoni, Simona Soverini, Serena Merante, Giuliana Alimena, Michele Baccarani, Rudiger Hehlmann, Anna Aventin, Anna Sureda, Jose-Roman Gomez, Justus Duyster, Gregor Verhoef, Giuseppe Saglio
Journal: Blood (2004)
Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.
Authors: Alan K. Burnett, Donald Milligan, Archie G. Prentice, Anthony H. Goldstone, Mary F. McMullin, Keith Wheatley
Journal: Blood (2004)
OA12.01 Phase II Randomized Study of 2 SBRT Regimens for Medically Inoperable Patients with Node Negative Peripheral NSCLC
Authors: Jorge A. Gomez Suescun, Gregory Videtic, Kevin Stephans, Jeffrey Bogart, Lili Tian, Adrienne Groman, Anurag K. Singh
Journal: Journal of Thoracic Oncology (2017)
Impact of ABO-Mismatch on Treatment Outcome and Transfusional Needs in Non-Myeloablative, Allogeneic, Peripheral Blood Stem Cell Transplantations
Authors: Nicole C Van Yperen, Inge GP Geelen, Con JMA Jöbses, Yvonne MC Henskens, Harry C. Schouten, Erik AM Beckers
Journal: Blood (2015)
Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT
Authors: Raya Mawad, Paul O'Donnell, Ted A. Gooley, Joseph G Rajendran, Darrell R. Fisher, Ajay K. Gopal, H. Joachim Deeg, Andrew Shields, Damian J. Green, David G. Maloney, Brenda M. Sandmaier, Rainer Storb, Frederick R. Appelbaum, Oliver W. Press, John M. Pagel
Journal: Blood (2012)
S66 Levels of salivary c-reactive protein, procalcitonin and neutrophil elastase can predict exacerbations in copd and determine those patients at high risk of re-exacerbation
Authors: N Patel, G Thorpe, P Jones, V Adamson, J Belcher, MA Spiteri
Journal: Thorax (2016)

Saliva has numerous practical advantages as a diagnostic bio-sample for management of long term conditions. We have previously demonstrated that C-reactive protein (CRP), procalcitonin (PCT) and neutrophil elastase (NE) can be reliably and reproducibly detected in saliva, offering useful information on health status. This study explores whether proactive monitoring of target analytes provides early warning of COPD exacerbations and re-exacerbation events. Salivary CRP, PCT and NE levels were determined weekly in 55 subjects with established COPD, known to be frequent exacerbators [GOLD Stage I, 7; Stage II, 24; Stage III, 19; Stage IV, 5]. Daily symptom scores were collected using a self-assessment electronic diary. Participants were monitored throughout their stable, prodromal (defined as the 7 days prior to exacerbation onset), exacerbation and post-treatment recovery periods. All three salivary biomarkers could distinguish stable status from onset of patient-defined exacerbations (CRP: p &lt; 0.003, PCT: p &lt; 0.001, NE: p &lt; 0.01); CRP median increase was 1.82 ng/ml, [interquartile range 4.79]; PCT 0.03 ng/ml [0.10] and NE 364 ng/ml [76]. Interestingly, increases over stable baseline were also observed in the prodromal period for salivary CRP 0.53 ng/ml [2.73], (p &lt; 0.001), PCT 0.08 ng/ml [0.01], (p &lt; 0.01) and NE 519 ng/ml [568], (p &lt; 0.007), occurring at 5.4 ± 1.8 days prior to patient-defined onset. Importantly, in those COPD patients experiencing more than 1 exacerbation (n = 15), re-exacerbator salivary CRP was significantly higher at the index exacerbation, 4.08 ng/ml [0.21], (p &lt; 0.04) with a mean time of 11 ± 8 days to re-exacerbation after treatment completion. Diary symptom analysis showed subjective deterioration in symptom trajectory 4 days prior to exacerbation onset (p &lt; 0.01), with re-exacerbators demonstrating a higher baseline symptom burden in the post-treatment period compared to single exacerbators (p &lt; 0.01). In conclusion, salivary biomarker levels can complement patient self-assessment to provide clinically useful cues to enable earlier identification of exacerbations in COPD; salivary CRP potentially offers additional information on re-exacerbation risk. These results support opportunities for patient-reported events and salivary biomarkers to be used synergistically in future near-patient COPD diagnostics for enhanced self-management and prompt exacerbation intervention.
TNF-α-238GA, IL-1α-889CC and IL-10–819CC Polymorphisms Confere an Increased Risk to Develop Multisystem Langerhans Cell Histiocytosis.
Authors: Paola De Filippi, Cesare Danesino, Diego Ferrarese, Annalisa De Silvestri, Carla Badulli, Antonino Trizzino, Paola Fidani, Alberto Garaventa, Alessandra Lombardi, Mariaclara Cuccia, Miryam Martinetti, Maurizio Aricò
Journal: Blood (2004)
Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors
Authors: Ifat Geron, Annelie Abrahamsson, Charlene Barroga, Edward Kavelerchik, Jason R. Gotlib, John D. Hood, Jeffrey Durocher, Chi Ching Mak, Glen Noronha, Richard Soll, Ayalew Tefferi, Kenneth Kaushansky, Catriona H.M. Jamieson
Journal: Blood (2007)
P2.02-048 Predictive Factors of Outcome in Locally Advanced NSCLC Patients Treated with Neo-Adjuvant Chemotherapy in Resource-Constrained Settings
Authors: Vinayakumar J. R, Sunil Kumar, Prabhat Malik, Surayanarayana Deo, Deepali Jain, Nootan Shukla
Journal: Journal of Thoracic Oncology (2017)
Stem Cell Transplantation in 281 Patients over 60 Years in Onco Hematologic Malignancies: A Single Center Experience.
Authors: Anne-Marie Stoppa, N. Vey, C. Faucher, R. Bouabdallah, F. Viret, C. Chabannon, P. Ladaique, D. Coso, A. Charbonnier, J.M. Schiano, P. Viens, J.A. Gastaut, D. Maraninchi, D. Blaise
Journal: Blood (2004)
P2.04-044 Mediastinal Neurogenic Tumors: Histopathological Characteristics and Surgical Treatment in a Single-Institutional Experience
Authors: Fatmir Caushi, Danjela Xhemalaj, Hasan Hafizi, Jona Shkurti, Ilir Skenduli, Zyber Pupla, Eljana Shima, Alban Hatibi
Journal: Journal of Thoracic Oncology (2017)
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
Authors: Kai-chao Feng, Ye-lei Guo, Yang Liu, Han-ren Dai, Yao Wang, Hai-yan Lv, Jian-hua Huang, Qing-ming Yang, Wei-dong Han
Journal: Journal of Hematology & Oncology (2017)

Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) immunotherapy represents a novel strategy for the management of many malignancies. However, the potential of CART therapy in treating advanced unresectable/metastatic CCA is uncharted so far. In this case, a 52-year-old female who was diagnosed as advanced unresectable/metastatic CCA and resistant to the following chemotherapy and radiotherapy was treated with CART cocktail immunotherapy, which was composed of successive infusions of CART cells targeting epidermal growth factor receptor (EGFR) and CD133, respectively. The patient finally achieved an 8.5-month partial response (PR) from the CART-EGFR therapy and a 4.5-month-lasting PR from the CART133 treatment. The CART-EGFR cells induced acute infusion-related toxicities such as mild chills, fever, fatigue, vomiting and muscle soreness, and a 9-day duration of delayed lower fever, accompanied by escalation of IL-6 and C reactive protein (CRP), acute increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, and grade 2 lichen striatus-like skin pathological changes. The CART133 cells induced an intermittent upper abdominal dull pain, chills, fever, and rapidly deteriorative grade 3 systemic subcutaneous hemorrhages and congestive rashes together with serum cytokine release, which needed emergent medical intervention including intravenous methylprednisolone. This case suggests that CART cocktail immunotherapy may be feasible for the treatment of CCA as well as other solid malignancies; however, the toxicities, especially the epidermal/endothelial damages, require a further investigation. ClinicalTrials.gov NCT01869166 and NCT02541370 .
P1.07-008 Lomustine Endoxan VP16 as Second or Further Line for Recurrent or Progressive Brain Metastases from SCLC
Authors: Charles Naltet, Audrey Dugué, Catherine Dubos, Pascal Dô, Serge Danhier, Delphine Lerouge, Christos Chouaid, Radj Gervais
Journal: Journal of Thoracic Oncology (2017)
MicroRNA analysis as a potential diagnostic tool in the cytological diagnosis of non-small cell lung cancer.
Authors: A. Fassina, R. Cappellesso, A. Olivotto, M. Fassan
Journal: Journal of Clinical Oncology (2011)

10605 Background: Advances in targeted therapy strictly require the accurate classification of non–small cell lung cancers (NSCLC). This might be difficult in small specimens obtained by fine-needle aspiration (FNA). MicroRNA are short non-coding genes playing significant roles in tissue differentiation. Recently, miRNAs expression profiles have been demonstrated to be useful in differentiating lung adenocarcinoma (AD) versus squamous cell carcinoma (SCC) in resected material. Aim of this study was to demonstrate microRNA diagnostic value in NSCLC sub-typing in cytology. Methods: From 2008 to 2010, 31 patients with a final diagnosis of NSCLC at FNA were retrieved from the archives of the Pathology and Cytopathology Dpt of the University of Padova and classified as AD or SCC based on their morphology and immunocytochemistry. Three slides were stained for cytopathology, while from the material of a second aspiration and from needle lavage RNA was extracted for qRT-PCR analysis of hsa-let-7 family and hsa-miR-205 expression. Results: A final diagnosis of AD was achieved in 18 cases, whereas 13 were SCC. qRT-PCR analysis showed that hsa-let-7a, hsa-let-7b, hsa-let-7c, hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 were significantly down-regulated, while hsa-miR-205 was significantly up-regulated in SCC compared to AD specimens (all p<0.05; t-test). Conclusions: hsa-let-7 family and hsa-miR-205 expression profiles could consistently differentiate AD from SCC, even in cytological material. Further multi-institutional studies should investigate the reliability of this remarkable novel diagnostic tool for sub-classifying NSCLC.
Two New Classes of Drugs to Target Chemotherapy Resistant and High Risk B-ALL
Authors: Cathy A. Swindlehurst, Leah Fung, Kyle W.H. Chan, Sabine Ottilie, Ashkan Shahbandi, Christopher L. Morris, Oliva L Francis, Terrence Bennet, Shannalee R Martinez, Kimberly J Payne
Journal: Blood (2011)
P156 Efficacy, safety and tolerability of once-daily tiotropium respimat® add-on therapy in children with moderate symptomatic asthma
Authors: O Schmidt, E Hamelmann, C Vogelberg, I Laki, G El Azzi, M Engel, P Moroni-Zentgraf, H Finnigan, M Vandewalker
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> A Phase II trial has shown that tiotropium Respimat® (tioR) is an effective, safe, and well-tolerated bronchodilator in patients aged 6–11 years with moderate symptomatic asthma.<sup>1</sup> To further assess the efficacy and safety of once-daily tioR add-on therapy, a Phase III trial was carried out in patients aged 6–11 years with moderate symptomatic asthma. <h3>Methods</h3> This 48-week, Phase III, randomised, double-blind, placebo-controlled, parallel-group study (CanoTinA-asthma®; NCT01634139) was performed in patients aged 6–11 years with moderate symptomatic asthma. Patients received once-daily tioR 5μg (2 puffs, 2.5 µg), tioR 2.5 μg (2 puffs, 1.25 µg) or placebo Respimat® (pboR; 2 puffs) as add-on to maintenance treatment of at least medium-dose inhaled corticosteroid (ICS) (200–400 µg budesonide or equivalent) alone or in combination with another controller medication. The primary end point was peak FEV1 within 3 hours post-dosing (FEV1(0–3 h)). Secondary end points included trough FEV1 (key end point), FEV1 area under the curve (AUC) (0–3 h), and peak FVC (0–3 h); all measured as response (change from baseline) at Week 24. Adverse events (AEs) were analysed descriptively. <h3>Results</h3> Of 403 patients randomised, 401 were treated. Baseline demographics and disease characteristics were balanced between treatment groups. TioR 5 µg and 2.5 µg provided statistically significant improvements in lung function versus pboR at Week 24 (Table) with adjusted mean difference ± standard error peak FEV1 (0–3 h) improvements of 164 ± 31 ml (p &lt; 0.0001) and 170 ± 31 ml (p &lt; 0.0001), respectively. The frequency of patients with AEs was similar across treatment arms, with a low incidence of drug-related and serious AEs (Table); no deaths occurred. The most common AEs were asthma worsening/exacerbation (lower incidence in tioR 5µg and 2.5 µg [34.1% and 36.3%] vs pboR [43.5%]), decreased peak expiratory flow rate (21.5% and 23% vs 20.6%), nasopharyngitis (8.9% and 11.1% vs 9.9%) and respiratory tract infection (9.6% and 8.1% vs 12.2%). <h3>Conclusion</h3> In patients aged 6–11 years with moderate symptomatic asthma, once-daily tioR add-on to ICS with or without other maintenance therapy significantly improves lung function compared with pboR. The safety profile of tioR was similar to that of pboR. <h3>Reference</h3> Vogelberg C, <i>et al</i>. <i>Respir Res</i> 2015;<b>16</b>(1):20. Please refer to page A272 for declarations of interest in relation to abstract P156.
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Authors: Gregg W. Stone, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, John D. Carroll, Barry D. Rutherford, Alexandra J. Lansky
Journal: New England Journal of Medicine (2002)

As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the infarct-related artery remain problematic. When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes.